Revenue beat expectations and EPS came in as expected, but net profit fell by nearly 30%—the earnings report itself isn’t the main story for Bio-Techne. The key is that the stock is now just $0.22 below the $73 acquisition price.
Bio-Techne ($TECH) reported its Q1 FY2027 results on November 6: adjusted EPS was $0.44, in line with consensus; revenue was $299.7 million, about $7.11 million above the $292.6 million consensus and up 4.6% year over year. But under GAAP, net income was $28.3 million, or $0.18 per share, down from $38.2 million, or $0.24 per share, in the same period last year—a decline of about 26%.
What’s really anchoring the stock price is something else: in June, Germany’s Merck KGaA announced an all-cash acquisition of Bio-Techne for $73 per share, valuing the deal at about $11.3 billion and representing a premium of roughly 36%. Shareholders have already approved the deal, the U.S. antitrust waiting period has expired, and the transaction is expected to close by the end of 2026 or early 2027.
Bio-Techne shares closed at $72.78 on November 6, up a modest 0.17%. They’re up about 23.8% year to date, giving the company a market cap of roughly $11.4 billion. The company also announced a quarterly dividend of $0.08 per share, payable on November 23.
This whale sees three possible scenarios: If the deal closes smoothly and there’s clear progress before year-end, the $0.22 discount marks the arbitrage opportunity, and the stock will remain anchored near $73. If closing slips into next year with no news, the discount will gradually widen. If the deal hits a snag, even strong earnings won’t cushion the blow. The earnings report itself is more of a “status update”: the revenue beat shows demand is still there, but the drop in net income shows costs are eating into profits. For a stock like this, this whale is watching the deal timeline, not the earnings figures.
Bio-Techne ($TECH) reported its Q1 FY2027 results on November 6: adjusted EPS was $0.44, in line with consensus; revenue was $299.7 million, about $7.11 million above the $292.6 million consensus and up 4.6% year over year. But under GAAP, net income was $28.3 million, or $0.18 per share, down from $38.2 million, or $0.24 per share, in the same period last year—a decline of about 26%.
What’s really anchoring the stock price is something else: in June, Germany’s Merck KGaA announced an all-cash acquisition of Bio-Techne for $73 per share, valuing the deal at about $11.3 billion and representing a premium of roughly 36%. Shareholders have already approved the deal, the U.S. antitrust waiting period has expired, and the transaction is expected to close by the end of 2026 or early 2027.
Bio-Techne shares closed at $72.78 on November 6, up a modest 0.17%. They’re up about 23.8% year to date, giving the company a market cap of roughly $11.4 billion. The company also announced a quarterly dividend of $0.08 per share, payable on November 23.
This whale sees three possible scenarios: If the deal closes smoothly and there’s clear progress before year-end, the $0.22 discount marks the arbitrage opportunity, and the stock will remain anchored near $73. If closing slips into next year with no news, the discount will gradually widen. If the deal hits a snag, even strong earnings won’t cushion the blow. The earnings report itself is more of a “status update”: the revenue beat shows demand is still there, but the drop in net income shows costs are eating into profits. For a stock like this, this whale is watching the deal timeline, not the earnings figures.
